Calculus Capital

What is Calculus Capital?

Calculus Capital is a venture capital firm based in London that focuses on investing in companies across various stages of growth, including seed, Series A, Series B, Series C, and Pre-IPO rounds. They invest in EIS/VCT qualifying companies and are sector-agnostic, although a significant portion of their portfolio comprises technology (specifically B2B SaaS) and healthcare companies.

They offer a broad range of investments across different sectors, emphasizing innovation and the creation of jobs and opportunities throughout the UK. Their investment approach targets companies driving innovation in technology, advancing healthcare, and contributing to the creative industries.

In terms of financial commitment, Calculus Capital typically invests between £1 million and £4 million, with a sweet spot investment of around £2.5 million. Their anticipated hold period for investments is between 3-5 years.

In the technology space, they show a preference for companies with a B2B sales model and an Annual Recurring Revenue of approximately £0.75-1 million. Within the healthcare sector, their investments are directed towards proprietary IP-led, clinical-stage companies.

Additionally, through their Creative Content Fund, they support companies that produce creative content. This fund is backed by the BFI, implying a keen interest in the UK's advertising, entertainment, and media content industries. The website content highlights Calculus Capital's commitment to backing innovators, experts, and game-changers, including examples of their portfolio companies in advertising, production, gene therapies, and workforce scheduling solutions.

What they say:

We invest in EIS/VCT qualifying companies. Even though the majority of our portfolio is made up of technology (B2B SaaS) and healthcare companies, we are sector agnostic and have a number of investments across other sectors. Our cheque size is in the range of £1.5-2.5m and we have an anticipated hold period of 3-5 years. In the technology space, we prefer companies with a B2B sales model and ARR of ~£0.75-1m. Meanwhile, in healthcare, we invest in proprietary IP-led, clinical-stage companies. We also fund companies which make creative content, through our Creative Content Fund, supported by the BFI.